Ernesto Pollano Promoted to General Sales Manager, Mexico / LATAM

MicroCare today announced the promotion of Ernesto Pollano to General Sales Manager, Mexico / LATAM. The promotion speaks to the company’s strategy to continue to build upon its global expansion.

Ernesto Pollano who joined MicroCare 2018 as Regional Sales Manager, Western Mexico, immediately distinguished himself for his keen problem-solving sales approach and customer relationship building abilities. His contributions to the success of MicroCare in the competitive Mexico market were recognized – and rewarded with today’s announcement.

In his new role, Ernesto Pollano will lead MicroCare sales and marketing in Mexico and Latin America. He will develop and grow the sales organization, strengthen relationships with distributors and manufacturers representatives, develop key new partnerships to increase revenue across all MicroCare product platforms, and identify strategic opportunities to increase sales in Mexico. Pollano will also play a key part in developing the MicroCare strategy specifically for Costa Rica and Dominican Republic.

Vince Libercci, Electronics Commercial Sales Manager says, “Ernesto has successfully increased the MicroCare market share in Mexico in the four years he has been with the company. He has demonstrated leadership, team building and strategic business development skills and is deserving of this appointment. We will lean on Ernesto to be our point person in an area that has been a key pillar to our growth and will be an important part of our future success.”

“I’m excited to lead the way on our growth plan for Mexico / LATAM,” says Pollano, an alumnus of the Universidad Panamericana, Guadalajara. “MicroCare is well positioned to grow in the critical cleaning market that it has called home for 40 years. Our unique offerings, including cleaning fluids and proprietary cleaning tools along with our strategic distributor partnerships worldwide, provide our clients with a value proposition that is unmatched in the industry.”

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”